Spruce Biosciences (SPRB) Long-Term Debt Repayments (2021 - 2025)
Spruce Biosciences (SPRB) posted quarterly Long-Term Debt Repayments of $841000.0 for Q4 2025, up 107.14% year-over-year from $406000.0 in Q4 2024, and up 107.65% quarter-over-quarter from $405000.0 in Q3 2025.
Spruce Biosciences (SPRB) Long-Term Debt Repayments (2021 - 2025) Analysis & Trends
Spruce Biosciences (SPRB) has reported Long-Term Debt Repayments for 4 consecutive years, with $841000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Debt Repayments rose 107.14% year-over-year to $841000.0; the TTM figure through Mar 2026 stood at $1.7 million (up 1.85% YoY), while the FY2025 annual figure was $2.1 million, up 26.82% from the prior year.
- Long-Term Debt Repayments climbed to $841000.0 in Q4 2025 per SPRB's latest filing, from $405000.0 in the prior quarter.
- Across five years, Long-Term Debt Repayments topped out at $4.8 million in Q1 2021 and bottomed at $405000.0 in Q1 2023.
- Historically, Long-Term Debt Repayments has averaged $774692.3 across 4 years, with a median of $406000.0 in 2023.
- Annual changes were most pronounced in 2024 — Long-Term Debt Repayments changed 0.0% — and 2025, when it surged 107.14%.
- Spruce Biosciences' Long-Term Debt Repayments stood at $4.8 million in 2021, then slumped by 91.49% to $406000.0 in 2023, then changed by 0.0% to $406000.0 in 2024, then jumped by 107.14% to $841000.0 in 2025.
- Business Quant data shows SPRB's Long-Term Debt Repayments at $841000.0 in Q4 2025, $405000.0 in Q3 2025, and $406000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Repayments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 17.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -10.01 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 841,000.00 |
| Dec 31, 2025 | 841,000.00 |
| Sep 30, 2025 | 405,000.00 |
| Sep 30, 2025 | 405,000.00 |
| Jun 30, 2025 | 406,000.00 |
| Jun 30, 2025 | 406,000.00 |
| Mar 31, 2025 | 405,000.00 |
| Mar 31, 2025 | 405,000.00 |
| Dec 31, 2024 | 406,000.00 |
| Dec 31, 2024 | 406,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Sep 30, 2024 | 405,000.00 |
| Jun 30, 2024 | 406,000.00 |
| Jun 30, 2024 | 406,000.00 |
| Mar 31, 2024 | 405,000.00 |
| Mar 31, 2024 | 405,000.00 |
| Dec 31, 2023 | 406,000.00 |
| Dec 31, 2023 | 406,000.00 |
| Sep 30, 2023 | 405,000.00 |
| Sep 30, 2023 | 405,000.00 |